118 related articles for article (PubMed ID: 1521741)
1. A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP.
Pollard HB; Dhariwal K; Adeyemo OM; Markey CJ; Caohuy H; Levine M; Markey S; Youdim MB
FASEB J; 1992 Sep; 6(12):3108-16. PubMed ID: 1521741
[TBL] [Abstract][Full Text] [Related]
2. L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.
Adeyemo OM; Youdim MB; Markey SP; Markey CJ; Pollard HB
Eur J Pharmacol; 1993 Aug; 240(2-3):185-93. PubMed ID: 8243537
[TBL] [Abstract][Full Text] [Related]
3. A model of MPTP-induced Parkinson's disease in the goldfish.
Weinreb O; Youdim MB
Nat Protoc; 2007; 2(11):3016-21. PubMed ID: 18007638
[TBL] [Abstract][Full Text] [Related]
4. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
5. The MPTP-induced parkinsonian syndrome in the goldfish is associated with major cell destruction in the forebrain and subtle changes in the optic tectum.
Pollard HB; Kuijpers GA; Adeyemo OM; Youdim MB; Goping G
Exp Neurol; 1996 Nov; 142(1):170-8. PubMed ID: 8912908
[TBL] [Abstract][Full Text] [Related]
6. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
7. (1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Lu Z; Wang J; Li M; Liu Q; Wei D; Yang M; Kong L
Chem Biol Interact; 2014 Nov; 223():18-26. PubMed ID: 25242684
[TBL] [Abstract][Full Text] [Related]
8. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
9. MPTP-induced "parkinsonism" in the goldfish.
Youdim MB; Dhariwal K; Levine M; Markey CJ; Markey S; Caohuy H; Adeyemo OM; Pollard HB
Neurochem Int; 1992 Mar; 20 Suppl():275S-278S. PubMed ID: 1365442
[No Abstract] [Full Text] [Related]
10. Effect of MPTP on dopaminergic neurons in the goldfish brain: a light and electron microscope study.
Goping G; Pollard HB; Adeyemo OM; Kuijpers GA
Brain Res; 1995 Jul; 687(1-2):35-52. PubMed ID: 7583312
[TBL] [Abstract][Full Text] [Related]
11. A simple quantitative bradykinesia test in MPTP-treated mice.
Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
[TBL] [Abstract][Full Text] [Related]
12. MPTP toxicity: implications for research in Parkinson's disease.
Kopin IJ; Markey SP
Annu Rev Neurosci; 1988; 11():81-96. PubMed ID: 3129982
[TBL] [Abstract][Full Text] [Related]
13. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.
Snyder SH; D'Amato RJ
Neurology; 1986 Feb; 36(2):250-8. PubMed ID: 3080696
[TBL] [Abstract][Full Text] [Related]
14. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
Taylor JR; Elsworth JD; Roth RH; Sladek JR; Redmond DE
Neuroscience; 1997 Dec; 81(3):745-55. PubMed ID: 9316026
[TBL] [Abstract][Full Text] [Related]
15. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
[TBL] [Abstract][Full Text] [Related]
16. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
Kopin IJ
Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621
[No Abstract] [Full Text] [Related]
17. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
18. The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Marsden CD; Jenner PG
Ciba Found Symp; 1987; 126():239-56. PubMed ID: 3556086
[TBL] [Abstract][Full Text] [Related]
19. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
[TBL] [Abstract][Full Text] [Related]
20. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and gamma-vinyl-gamma-aminobutyric acid (gamma-vinyl GABA) alter neurotransmitter concentrations in the nervous tissue of the goldfish (Carassius auratus) but not the cockroach (Periplaneta americana).
Sloley BD; McKenna KF
Neurochem Int; 1993 Feb; 22(2):197-203. PubMed ID: 8094992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
